Boys Arnold & Co. Inc. decreased its position in Celgene Co. (NASDAQ:CELG) by 35.6% during the 1st quarter, HoldingsChannel reports. The fund owned 5,279 shares of the biopharmaceutical company’s stock after selling 2,917 shares during the quarter. Boys Arnold & Co. Inc.’s holdings in Celgene were worth $498,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the stock. Investors Research Corp acquired a new stake in Celgene during the first quarter worth approximately $28,000. Creative Financial Designs Inc. ADV raised its holdings in Celgene by 1,968.8% during the first quarter. Creative Financial Designs Inc. ADV now owns 331 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 315 shares in the last quarter. Bruderman Asset Management LLC acquired a new stake in Celgene during the fourth quarter worth approximately $25,000. Murphy Pohlad Asset Management LLC acquired a new stake in Celgene during the fourth quarter worth approximately $25,000. Finally, Athena Capital Advisors LLC acquired a new stake in Celgene during the fourth quarter worth approximately $27,000. 71.71% of the stock is currently owned by hedge funds and other institutional investors.

CELG has been the topic of a number of research analyst reports. Cantor Fitzgerald cut shares of Celgene from an “overweight” rating to a “neutral” rating and set a $94.00 price objective on the stock. in a report on Friday, April 5th. ValuEngine cut shares of Celgene from a “hold” rating to a “sell” rating in a report on Wednesday, April 24th. BidaskClub cut shares of Celgene from a “hold” rating to a “sell” rating in a report on Thursday, April 25th. Cowen initiated coverage on shares of Celgene in a report on Tuesday, February 26th. They set a “market perform” rating and a $102.00 price objective on the stock. Finally, Zacks Investment Research cut shares of Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, April 3rd. Twenty analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $95.96.

Shares of Celgene stock opened at $94.96 on Thursday. The firm has a market capitalization of $66.40 billion, a PE ratio of 12.48, a price-to-earnings-growth ratio of 0.43 and a beta of 1.68. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $97.07. The company has a debt-to-equity ratio of 2.42, a quick ratio of 2.66 and a current ratio of 2.78.

Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, April 25th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.45 by $0.10. The business had revenue of $4.03 billion for the quarter, compared to analysts’ expectations of $4.01 billion. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The company’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the company posted $2.05 EPS. As a group, equities research analysts expect that Celgene Co. will post 9.85 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dailypolitical.com/2019/05/16/boys-arnold-co-inc-has-498000-position-in-celgene-co-celg.html.

Celgene Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Featured Article: What is the return on assets (ROA) ratio?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.